🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06817434
Recruiting Observational

Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease

NCT06817434 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Observational
Started
2024-12-15
Last updated
2025-02-10

Condition(s) studied

Moyamoya Disease

Investigational drug(s) / intervention(s)

Revascularization/Conservative management

Revascularization/Conservative management: Revascularization/Conservative management

Study summary

The purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. The imaging examination meets the diagnostic criteria for moyamoya disease; 2. Sign the informed consent form; 3. Age ≥18 years old; 4. Baseline mRS score ≤2 points; 5. The patient receives revascularization/conservative treatment; 6. There is at least 1 imaging follow-up result. Exclusion Criteria: 1. Patients with atherosclerosis, autoimmune diseases, meningitis, Down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of Moyamoya syndrome; 2. Individuals under the age of 18; 3. Participants who refuse to take part in this study; 4. Pregnant patients; 5. Those with concurrent intracranial aneurysms, cerebrovascular malformations, brain tumors, or hydrocephalus; 6. A history of stroke occurring more than three months prior to the diagnosis of Moyamoya disease; 7. Individuals with a history of coronary heart disease or previous cardiovascular and cerebrovascular surgical interventions, including cerebral revascularization, intracranial artery stent implantation, carotid artery stenting, endarterectomy, coronary artery bypass grafting, or coronary stent implantation; 8. Allergies to contrast media; 9. Patients with missing imaging data or whose image quality cannot be analyzed; 10. Individuals who refuse or are unable to undergo imaging follow-up; 11. Patients receiving other types of lipid-lowering drug treatments.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing China Recruiting

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06817434 on ClinicalTrials.gov ↗ ← All trials in China